Sort by:
Garris CS*, Arlauckas SP*, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Immunity. 2018;49:1-14 - PMID: 30552023 - PMCID: PMC6301092 - DOI: 10.1016/j.immuni.2018.09.024
Kartha VK, Alamoud KA, Sadykov K, Nguyen BC, Laroche F, Feng H, Lee J, Pai SI, Varelas X, Egloff AM, Snyder-Cappione JE, Belkina AC, Bais MV, Monti S, Kukuruzinska MA
Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer.
Genome Med. 2018;10(1):54 - PMID: 30029671 - PMCID: PMC6053793 - DOI: 10.1186/s13073-018-0569-7
Rosenbaum MW, Gigliotti BJ, Pai SI, Parangi S, Wachtel H, Mino-Kenudson M, Gunda V, Faquin WC
PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.
Endocr Pathol. 2018;29(1):59-67 - PMID: 29372535 - PMCID: PMC6500591 - DOI: 10.1007/s12022-018-9514-y
3 CSV